Turkish Pharmaceutical Reimbursed Market Up 6% In 2013 With Alimentary, Metabolism Products Top Drivers
This article was originally published in PharmAsia News
Turkey’s pharmaceutical market reached TL 15.3 billion ($6.92 billion) in 2013, gaining 6.4% to TL 13.7 billion ($6.19 billion) for reimbursed drugs, while non-reimbursed products gained 7% to TL 1.6 billion ($742.1 million).
You may also be interested in...
Turkey’s efforts to control rising rates of COVID-19 are compromising the ability of hospitals to pay their debts to medtech and pharmaceutical companies. The government has devised a payments plan, but there is catch.
The Turkish medtech industry’s ongoing hospital payments problems appeared likely to come back onto the government’s agenda, with the national economy recovering somewhat in late 2019. But COVID-19 dashed those hopes.
Growth prospects for Turkey’s medical technology market are significant, but local companies have complained about public policies that are harmful to business and about the ongoing crisis in the hospital system. Now, international medtechs are starting to react, with some downscaling local operations and portfolios. Association of Research Based Medical Technologies Manufacturers president Umut Gokalp laid out the problems being faced by industry, and what action he thinks the government should take.